2型糖尿病患者的危险因素、死亡率与心血管结局
该队列研究纳入瑞典国家糖尿病登记处271,174例2型糖尿病患者,按年龄、性别和县与1,355,870名对照匹配,中位随访5.7年,期间共175,345例死亡。以糖化血红蛋白、低密度脂蛋白胆固醇、白蛋白尿、吸烟、血压五项危险因素是否达标分层,每多一项达标,超额风险逐步下降。五项均达标的糖尿病患者与对照相比,全因死亡HR 1.06(95%CI 1.00–1.12)、急性心肌梗死HR 0.84(95%CI 0.75–0.93)、卒中HR 0.95(95%CI 0.84–1.07),但心衰住院风险持续升高(HR 1.45,95%CI 1.34–1.57)。糖尿病患者中,糖化血红蛋白超出目标范围是卒中和急性心肌梗死的最强预测因素,吸烟是死亡的最强预测因素。
要点
- 五项危险因素(糖化血红蛋白、低密度脂蛋白胆固醇、白蛋白尿、吸烟、血压)均达标的2型糖尿病患者,全因死亡HR 1.06(95%CI 1.00–1.12),与对照相比超额风险很小或没有。
- 五项均达标的糖尿病患者急性心肌梗死HR 0.84(95%CI 0.75–0.93)、卒中HR 0.95(95%CI 0.84–1.07),与对照相比未见超额风险。
- 糖尿病患者心衰住院风险持续高于对照,HR 1.45(95%CI 1.34–1.57),即使其他危险因素达标也未消除。
- 糖尿病患者中,糖化血红蛋白超出目标范围是卒中和急性心肌梗死的最强预测因素,吸烟是死亡的最强预测因素。
- 每有一项危险因素进入目标范围,2型糖尿病患者的超额结局风险逐步下降。
适用人群与场景
- 瑞典国家糖尿病登记处登记的271,174例2型糖尿病患者,按年龄、性别和县与1,355,870名对照匹配。
- 评估按年龄分层,并按五项危险因素(糖化血红蛋白升高、低密度脂蛋白胆固醇升高、白蛋白尿、吸烟、血压升高)是否超出目标范围分层。
诊断标准与关键阈值
- 五项危险因素变量为:糖化血红蛋白升高、低密度脂蛋白胆固醇升高、白蛋白尿、吸烟、血压升高;原文未给出各项的具体目标界值。
研究设计与关键结果
- 研究类型为队列研究,纳入271,174例2型糖尿病患者并与1,355,870名对照按年龄、性别和县匹配,中位随访5.7年,期间175,345例死亡。
- 五项变量均达标的糖尿病患者与对照相比:全因死亡HR 1.06(95%CI 1.00–1.12),急性心肌梗死HR 0.84(95%CI 0.75–0.93),卒中HR 0.95(95%CI 0.84–1.07)。
- 糖尿病患者心衰住院风险持续高于对照:HR 1.45(95%CI 1.34–1.57)。
- 在2型糖尿病患者中,糖化血红蛋白超出目标范围是卒中和急性心肌梗死的最强预测因素,吸烟是死亡的最强预测因素。
- 2型糖尿病患者中,每有一项危险因素变量进入目标范围,超额结局风险逐步下降。
证据类型、等级与局限
- 证据类型:队列研究(基于瑞典国家糖尿病登记处)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,五项危险因素变量均达标的2型糖尿病患者与一般人群相比,死亡、心肌梗死或卒中的超额风险似乎很小或没有。
- 糖尿病患者心衰住院风险持续高于对照(HR 1.45,95%CI 1.34–1.57),即使五项危险因素均达标也未消除。
- 糖尿病患者中糖化血红蛋白超出目标范围是卒中和急性心肌梗死的最强预测因素,吸烟是死亡的最强预测因素。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated.
METHODS: In a cohort study, we included 271,174 patients with type 2 diabetes who were registered in the Swedish National Diabetes Register and matched them with 1,355,870 controls on the basis of age, sex, and county. We assessed patients with diabetes according to age categories and according to the presence of five risk factors (elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, albuminuria, smoking, and elevated blood pressure). Cox regression was used to study the excess risk of outcomes (death, acute myocardial infarction, stroke, and hospitalization for heart failure) associated with smoking and the number of variables outside target ranges. We also examined the relationship between various risk factors and cardiovascular outcomes.
RESULTS: The median follow-up among all the study participants was 5.7 years, during which 175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of outcomes decreased stepwise for each risk-factor variable within the target range. Among patients with diabetes who had all five variables within target ranges, the hazard ratio for death from any cause, as compared with controls, was 1.06 (95% confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial infarction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 (95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside the target range was the strongest predictor of stroke and acute myocardial infarction; smoking was the strongest predictor of death.
CONCLUSIONS: Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. (Funded by the Swedish Association of Local Authorities and Regions and others.).
参考来源
- Rawshani A, Rawshani A, Franzén S, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018. PMID: 30110583. doi:10.1056/NEJMoa1800256
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。